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EDITORIAL REVIEW
Erythropoietin in the pathogenesis and treatment of the anemia
of chronic renal failure
Ever since Richard Bright in 1836 commented on the progres-
sive fading of the "healthy colors of the countenance" of his
kidney patients [1] anemia has been considered a hallmark of
chronic renal failure. The cause was assigned to a combination of
blood loss, hemolysis and bone marrow suppression, all induced
by the retention of toxic metabolites. However, when the kidneys
were found to be the main source of the erythroid growth factor,
eiythropoietin (Epo), the possibility was raised that the anemia
could be caused primarily by a deficient production of Epo. This
possibility was enhanced by the low Epo titers found in patients
with renal failure and by now is supported strongly by the
remarkable capacity of recombinant erythropoietin to alleviate
and even eliminate the anemia. The fact that intense dialysis,
androgens and the administration of various growth factors may
increase the concentration of hemoglobin independently shows
merely that erythropoiesis is affected by the metabolic environ-
ment. It does not, however, alter the position of erythropoietin as
the principal regulator of red cell production in normals as well as
in uremie individuals.
Erythropoietin in normal erythropoiesis
Production of Epo
In 1957 Jacobson and his colleagues reported that in response
to anemia the kidneys produce the then recently described
eiythroid growth factor, Epo [2]. For some years this conclusion
was bitterly opposed but eventually confirmed when it was shown
that isolated kidneys perfused with a serum-free medium respond
to hypoxia by synthesizing Epo [3]. That the kidneys have been
chosen for this task may have both evolutionary and functional
reasons. In some fish the kidneys also serve as red cell producing
organs [4] combining the production and action of Epo into one
site. In mammals the kidneys and bone marrow have evolved
separately, and the endocrine production of Epo appears to
supplement the vascular homeostatic function of the kidneys [5].
The rate of production of Epo by the kidneys is inversely
proportional to the oxygen carrying capacity of blood, and it
appears that the unique vascular structure of the kidneys render
them extremely sensitive to changes in oxygen supply [6]. This
renal sensitivity to oxygen and the capacity of Epo to stimulate the
production of oxygen carrying red cells provide an efficient
feedback mechanism which maintains an optimal supply of oxygen
to the tissues (Fig. 1) [7].
Erythropoietin is a glycoprotein with a molecular weight of
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30,500. It consists of a single strand of 165 amino acids and an
equal amount of attached carbohydrates [8]. It can be quantitated
by bioimmune, radioimmune or ELISA assays and its concentra-
tion in normal plasma ranges from 8 to 18 mU/ml or about 0.1
gIml. When an individual is exposed to hypoxia either due to
anemia or to environmental altitude its concentration increases
exponentially and may reach thousands of mU/mi (Fig. 2) [9].
The gene coding for Epo is located on chromosome 7 and
consists of five exons and four introns (Fig. 3) [10]. Its upstream
promoter is apparently not directly responsive to hypoxia but this
responsiveness is found in an enhancer located immediately
downstream from the gene [11, 12]. Recent studies have shown
that hypoxia initially causes the production of a protein named
HIF-1 for hypoxia inducible factor [13]. This factor binds to the
oxygen sensitive enhancer and acts as a transcription factor. HIF-1
is produced in response to hypoxia by many different cell types
and apparently acts as a general transcription factor for a number
of hypoxia inducible genes, such as those coding for platelet
derived growth factor and vascular endothelial growth factor as
well as for many glycolytic enzymes [14].
The five exons code for 166 amino acids, (one of which is lost
after translation) and for a leader sequence of 26 amino acids. In
vitro hybridization studies have shown that the mRNA is present
in interstitial cortical cells located near the base of the proximal
tubular cells (Fig. 4) [15]. These cells, possibly transformed
fibroblasts, transcribe the gene in an all or none fashion and the
rate of production can be correlated with the number of mRNA
containing cells [16]. The location of these cells would suggest that
oxygen sensing takes place in the highly oxygen dependent tubular
cells producing a short range signal to the less oxygen dependent
interstitial cells. However, the exact way in which oxygen is sensed
and translated into Epo gene activation has not been established.
Epo indistinguishable from that produced by the kidneys can
also be produced by hepatocytes and macrophages and possibly
even by erythroblasts. However, this extrarenal production does
not contribute more than 10 to 15% of total production in rats
[17] and possibly even less in humans. In no way can it compensate
for the loss of Epo production observed after total nephrectomy.
Although the rate of production of Epo is clearly related to the
degree of anemia and in turn to the supply of oxygen to the
tissues, this relationship is quite broad, suggesting that a number
of other factors play a role. Among potential agonists are cobalt
[18], androgens [19] and insulin-derived growth factors [201.
Antagonists include inflammatory cytokines such as tumor necro-
sis factor, IL-i and transforming growth factor 13 [21, 22]. It would
seem likely that toxic metaholites retained in patients with chronic
renal disease may also impair activation of the Epo gene hut
relevant observations are not available.
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Action of Epo
The transformation of a multipotential stem cell into a mature
red blood cell occurs in two morphologically distinct stages of
which only the first is responsive to Epo. This stage, the stem-and
progenitor cell stage, consists of small mononuclear cells display-
ing a specific glycophosphoprotein CD34 on their surface (Fig. 5)
[23]. In the second, the precursor stage, the cells appear as
morphologically recognizable erythroblasts.
Cells in the first stage can functionally be subdivided into
multipotential stem cells and unipotential committed progenitor
cells. The multipotential stem cells have the capacity for self-
renewal and for replenishing progenitor cells. This replenishment
appears to occur by chance "stochastically" [24] and is initiated
primarily by lineage, non-specific cytokines such as IL-3, stem cell
factor, insulin growth factor and GM-CSF. It appears that it is
after the transformation of a multipotential stem cell to a
unipotential progenitor cell that peripheral demands for cellular
production first can be met.
Erythroid progenitor cells have probably lost most of their
capacity for self-renewal but have gained receptors for erythro-
poietin. The earliest erythroid progenitor cells have receptors for
both lineage specific and lineage non-specific eytokines and when
exposed to an optimal concentration of these growth factors, will
proliferate luxuriously and produce a "burst" of colonies com-
posed of thousands of nucleated red blood cells [25]. As these
early BFU-Es (burst-forming units) mature their proliferation
becomes increasingly dependent on erythropoietin until as a
terminal progenitor cell the CFU-E (colony-forming unit) it will
only transform into precursor cells if erythropoictin is present.
The erythropoietin receptor is a 55,000 Da transmembrane pro-
tein belonging to the cytokine receptor super family [26]. When
Epo hinds to the extracellular domain, it initiates a cascade of
phosphorylations of intracellular proteins resulting in the release
of second messengers [27]. The exact signals transmitted by these
messengers are not well understood, but they obviously are
necessary for progenitor cell proliferation. It is unlikely that they
arc transcription factors for genes involved in the synthesis of
globin or other mature erythroid proteins, since the receptors are
present and active in very immature progenitor cells. It is more
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Hematocrit, volume %
Fig. 2. Relationship between erythropoietin levels and hematocrits in normal
individuals (A) and in anemic, nonuremic patients (U) (redrawn from data
in [9]).
likely that they are involved in maintaining viability of progenitor
cells [281. In vitro studies have shown that these cells in the
absence of erythropoietin will undergo apoptosis and die before
they reach the precursor cell stage. In the presence of erythropoi-
etin they will proliferate and eventually transform into a precursor
cell. The kinetics of progenitor cells in vivo appear very similar,
although the proliferation is somewhat more restrained and a
BFU-E even in the presence of large amounts of Epo will not
produce a burst of CFU-Es, but merely 50 to 100 CFU-Es [29]. In
the presence of a normal concentration of Epo (8 to 18 mU/ml)
each BFU-E probably makes no more than 4 to 6 CFU-Es.
At a certain level of maturation the erythroid genes in surviving
CFU-Es become activated and the cell is transformed into
hemoglobin synthesizing erythroblasts or precursor cells. Further
proliferation and maturation of these cells do not appear to be
affected by Epo or other growth factors and will proceed at a fixed
rate in the presence of adequate supplies of B12 folic acid and
iron. Eventually the nucleus is extruded and the cytoplasm will
become first a hemoglobin synthesizing reticuloeyte and then a
mature red blood cell.
Erythropoietin in uremic erythropoiesis
In patients with chronic renal failure, anemia is an almost
invariable presence. The severity of the anemia is roughly propor-
tional to the severity of the azotemia as expressed by the urea
concentration or the creatinine clearance (Fig. 6) [30]. Because of
the slow progression of both renal disease and anemia many
patients adjust reasonably well to a reduction in hemoglobin
concentration, and their symptoms are usually not thought to be
related to such a reduction. Nevertheless, a chronic anemia in
patients with renal disease may cause left ventricular hypertrophy
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Fig. 1. A model of the feedback mechanism which controls the rate of red
cell production (redrawn from [7], with permission).
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Fig. 4. Sections of eiythropoietin-producing mouse kidneys. A. is stained by H and F and shows proximal tubular cells. B. In situ hybridization for Epo
mRNA indicating its cxtratubular localization (reproduced by permission from [15], with permission).
and can be considered an independent risk factor for survival [31].
Furthermore, the remarkable improvement in energy and vitality
observed after treatment with recombinant erythropoietin attest
to the fact that chronic anemia has a depressing action on the
quality of life. If untreated, the anemia eventually becomes severe
enough to cause cardiovascular failure and demand transfusion
replacement.
It is usually assumed that the anemia is caused in part by a
Fig. 3. A model of eiythropoietin synthesis from the DNA via mRNA to Epo polypeptide.
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Fig. 5. Model of red blood cell production from tnultipotential Stem cells through unipotential progenitor cells and differentiated precursor cells to mature red
blood cells. Receptors for erythropoietin and other cytokines are indicated. Stippled progenitor cells indicate potential apoptosis.
shortening of the lifespan of red cells. The cells are probably
intrinsically normal, since when labeled they will survive normally
after transfusion into a healthy recipient. In patients, the lifespan
is decreased often in direct proportion to the degree of azotemia
3O]. Many metabolic pathways in the red cells have been sus-
pected of being impaired but no single defect has been shown to
be responsible for premature destruction. Neither has it been
possible to identi' a specific red cell toxin. Whatever it is, it
appears to be dialyzable since the red cell lifespan in carefully
managed and dialyzed patients may he near normal or even
normal [32].
Toxic interference with both Epo production and action has
also been invoked in the pathogenesis of the anemia. The effect of
intensive dialysis on these processes, however, has been contro-
versial and it appears that the mere reduction in kidney mass and
in the number of Epo-synthesizing cells could alone explain the
development of an anemia.
Production of Epo
Numerous studies in animals and humans have shown convinc-
ingly that renal injury causing secretory failure is invariably
associated with impaired oxygen sensing and Epo production [33].
Although the plasma titer of Epo in renal failure often remains
within normal limits (Fig. 7) [34], it fails to show an adequate
compensatory rise in response to blood loss resulting in a decrease
in the concentration of hemoglobin. This decrease may become
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arrested in patients with stable renal failure or aggravated if the
disease is progressive and the production of Epo is further
curtailed. Even the most severely impaired kidneys, however, are
capable of bursts of Epo production in response to a sudden
aggravation of the anemic hypoxia, but the response is not
sustained and the rate of red cell production is not significantly
increased [35]. The possibility that toxic metabolites as well as
depressive cytokines play a role in the reduction of Epo synthesis
cannot be ruled out, but intense dialysis does not change Epo
titers appreciably [36].
Action of Epo
A number of metabolites retained in renal failure have been
implicated as potential erythropoietic toxins. Among these are
various amines, including spermine [37] as well as the parathyroid
hormone [38]. These substances, however, have eventually been
found to be general bone marrow toxins and not specific suppres-
sors of red cell production [39]. Furthermore, when the effective-
ness of recombinant Epo was evaluated, it was shown to have the
same erythropoietic effect in normals as in uremic patients,
suggesting the absence of a specific uremic toxin [401. Neverthe-
less, it has also been reported that the response to recombinant
Epo in stable, adequately dialyzed patients is about 1/2 of that in
normal individuals (Fig. 8) [32, 41]. Consequently, it appears that
erythroid suppression by a still unknown uremic toxin may play a
contributory role in the development of anemia.
Treatment with erythropoietin
The logical consequence of the above listed observations is to
consider the anemia of chronic renal failure as a deficiency
disease. In the past, a few brave but inconclusive attempts were
made to treat patients with Epo isolated from the urine of anemic
individuals [42]; however, it was in the middle 80's with the
availability of recombinant human Epo that clinical trials became
possible [43, 44]. Since then replacement therapy with recombi-
nant human Epo has become the most rational therapy for the
anemia of chronic renal failure worldwide [45]. Most treated
Hematocrit, volume %
Fig. 7. Relationship between etythropoietin levels and hematocrit in patients
with renal failure (A) and in anephric patients (0) (redrawn from data in
/34]).
dialysis patients increase their hematocrit in a dose-dependent
manner (Fig. 9) [44]. The use of anabolic steroids has been largely
abolished and the employment of transfusions has been relegated
to the treatment of acute episode of symptomatic hypoxia.
The treatment with recombinant Epo has resulted in a remark-
able improvement in global well being and quality of life [46—49],
and has disclosed that many symptoms formerly attributed to
uremia (fatigue, cold intolerance, mental sluggishness, impo-
tence) respond to the correction of anemia. Furthermore, the
elimination of anemia has been beneficial for a number of
co-morbid conditions introduced by the aging and prevalence of
diabetes among patients initiating dialysis. Improvement has been
observed in aerobic capacity [50], in cardiac [51], muscle [52],and
immunologic function [53, 51 and in diabetic retinopathy [55].
This global success in dialysis patients has motivated the
subsequent use of recombinant human Epo in pre-dialysis pa-
tients showing progressive renal failure. Initial concerns of accel-
erating renal function deterioration in patients with progressive
renal failure have not been substantiated. No significant alteration
in the progression of renal disease [56—61] has been noted.
However, avoidance of renal function deterioration requires
careful control of blood pressure before or soon after starting
recombinant human Epo through the aggressive use of antihyper-
tensive agents. Slow correction of anemia by using lower starting
doses is advocated by some [621 since such an approach, particu-
larly in children, tends to improve the glomerular filtration rate as
assessed indirectly.
Worldwide, new or worsening arterial hypertension develops in
up to 30% to 40% of treated patients, with the greatest increases
affecting daytime systolic and overnight diastolic pressures [63].
Hypertension may develop within two weeks or not for four to six
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Fig. 8. Rate of red cell production as related to plasma concentrations of
etythropoietin in 22 stable uremic patients. Due to their stable hematocrits
the rate of red cell production must equal the rate of red cell destruction
which was calculated by dividing red cell mass by red cell life span. The
square denotes the rate of red cell production in normal individuals at
normal erythropoietin levels (reproduced by permission from [41]).
months. Risk factors for hypertension include pre-existing hyper-
tension, severe anemia at initiation, rapid increase in hematocrit,
high recombinant human Epo doses given intravenously, and the
presence of native kidneys [63]. The mechanisms producing
hypertension with recombinant human Epo therapy are likely to
be multifactorial: loss of hypoxic vasodilation [64], changes in
blood viscosity, in activation of renin-angiotensin system [65], in
blood volume [661, or through a direct vascular effect. This last
mechanism may involve increased synthesis of endothelin-1, in-
creased vascular calcium uptake, and platelet-dependent mito-
genie action [67], The role of recombinant human Epo therapy in
raising plasma endothelin-1 to levels, which directly can increase
pressure remains controversial [68].
Nevertheless, if body wt and interdialytic fluid gains are con-
trolled in dialysis patients, systolic and diastolic blood pressure
remain virtually unchanged despite significant increases in hemat-
ocrit [69]. Similar observations have been reported for predialysis
patients [70]. Many of these predialysis patients need aggressive
diuretic therapy during recombinant human Epo treatment to
maintain constant blood volume and thus avoid hypertension.
Regression of left ventricular hypertrophy (LVH) [711, reduc-
tion of left ventricular volume [51] and improvement in exercise
induced ST-segment depression [72] may occur following partial
correction of anemia. Improvements in exercise and cardiorespi-
ratory performance observed at a hematocrit of 30% to 36% are
maintained for at least one year [73].
Following correction of anemia, incremental changes in serum
potassium, phosphate, and creatinine are small [74]. The effects
on the urea kinetic modeling parameter, Kt/V [75] and on dialyzer
reuse efficiency [76] are easily corrected by changing the dialysis
prescription and by increasing the heparin dosing by 15 to 40%.
With peritoneal dialysis, clearances of sodium, potassium, and
urea and changes in protein loss or glucose absorption do not
change after recombinant human Epo therapy [77]. Decreases in
phosphate clearance can be affected by short dwell times. The
only other concern arising from the use of recombinant human
Epo therapy is that relating to access thrombosis. The studies to
date have been equivocal [78, 79] and the risk of thrombosis in
prosthetic bridge grafts is difficult to assess.
The major issues regarding the clinical use of recombinant
human Epo in patients with renal disease are cost effectiveness,
dosage, route of administration and resistance to therapy. Many
of these aspects were recently reviewed and discussed [80].
Compared to alternative treatments (androgens and transfu-
sions), costs have increased from the use of recombinant human
Epo for end-stage renal disease in the USA [81]. Savings from
reductions in hospital admissions appear late requiring patient
survival for at least 18 months [82].
In the U.S., the upper target hematocrit limit has been extended
to 36% while in many parts of the world, the target range remains
28 to 33%. Response to recombinant human Epo is dose-
dependent, but interindividual variance is large. The ideal dose in
a given patient should permit attainment of the target hematocrit
over the life span of the erythroeyte (4 months). The same dose
should be used to maintain a stable hematocrit at the desired level
[83]. In order to obtain a 0.5 to 1.0 point increase in hematocrit
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per week (Fig. 9, ref. 44), a reasonable initiating dose is 50 U/kg
given intravenously three times per week with dose adjustments of
10 U/kg made every four weeks. Now that dead space syringes and
a multi-dose 20,000 U vials are available, it is no longer necessary
to adjust the dose to the nearest unit dose vial.
Subcutaneous injections may be the most effective route of
administration and with modern formulations are associated with
minimal discomfort. Subcutaneous dosing permits the achieve-
ment of sustained levels in the interdialytic period [841. Low
trough levels in the interdialytic period following intravenous
injection result in intermittent eiythropoiesis. The majority of
studies show lower dosage requirements using the subcutaneous
rather than those using the intravenous route [44, 85]. Although
dosing at less than three-times-a-week is frequent, particularly in
pre-dialysis or CAPD patients, we believe that cost-effectiveness is
compromised.
Suboptimal response to recombinant human Epo most com-
monly results from failure of an adequate delivery of iron to the
erythron. Enhanced iron utilization due to erythropoietin-induced
red blood cell formation can quickly deplete iron stores previously
reduced by poor iron absorption, occult gastrointestinal bleeding,
or dialysis related blood losses. Oral iron preparations remain the
most cost-effective form of maintenance. A randomized study
however, has demonstrated that iron replete patients receiving
regular parenteral iron maintain better serum ferritin levels and
require less recombinant human Epo than patients receiving
regular oral iron [86]. The dose of recombinant human Epo dose
was significantly reduced by the use of chronic intravenous iron
supplementation that elevated serum ferritin into the 700 ng/ml
range [87]. Regular monitoring of iron status by measurement of
serum ferritin and transferrin saturation is mandatory in the
cost-effective management of anemia with recombinant human
Epo. In our experience, it is difficult for most dialysis patients to
take more than 130 mg of elemental iron orally per day and avoid
gastrointestinal intolerance. The typical in-center hemodialysis
patient invariably requires iron. When iron indices indicate frank
or impending iron deficiency, parenteral iron is most commonly
administered as intermittent doses totaling 1000 mg during con-
secutive dialysis treatments. Two to four courses of parenteral
iron may be needed annually. CAPD patients require less iron due
to smaller ongoing blood losses. In most such cases, administra-
tion of 500 or 1000 mg slowly over four to six hours is sufficient
and adequate response can be maintained for a year.
Currently the erythropoietic effectiveness of recombinant hu-
man Epo is being tested in the treatment of patients with a
number of different anemias [88]. In the treatment of the anemia
of chronic renal failure, however, its effectiveness has by now been
solidly established with more than 90% of carefully treated
dialysis patients responding [891. Iron deficiency or inadequate
dialysis may reduce its effectiveness [90] and complicating ill-
nesses such as acute or chronic infiammations [91], hyperparathy-
roidism [92] and sickle cell anemia may render the patient
refractory to treatment. The emergence of Epo antibodies has
been documented [93] but must be an extremely rare event.
Although the presence of still unidentified uremic toxins may
reduce the erythropoietic effectiveness of recombination Epo,
such a reduction is easily overcome by increasing the amount of
recombinant Epo administered.
In conclusion, recombinant human erythropoietin has been
found to be a safe and extremely effective agent in the treatment
of anemia of chronic renal failure.
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